3 years ago

Transine Therapeutics Secures £13.7M Seed Funding for Therapeutic RNA Platform

  • Transine Therapeutics, a Cambridge, UK-based biotechnology company, raised £13.7M in Seed funding led by Epidarex Capital with participation from Dementia Discovery Fund (DDF)

  • The company intends to use the funds to further exploit its SINEUP® platform and accelerate the development of its product portfolio, building on recent advances with its lead programs in Central Nervous System and Ophthalmology indications with key in vivo data expected this year

  • Transine Therapeutics is an RNA platform company developing a novel class of therapeutic RNAs (SINEUPs) capable of upregulating protein expression with a level of control and specificity across a high range of diseases and applications.

      • ProblemHealthcare

      "Current treatments for diseases like those in the Central Nervous System and Ophthalmology are often ineffective or have serious side effects. Small molecules, conventional biologics, and gene therapies can't address many of these diseases."

      Solution

      "Transine Therapeutics has developed a novel RNA platform called SINEUP® that can precisely target and enhance the translation of mRNA, boosting the expression of any chosen target protein. This allows for the development of new, highly specific treatments for a wide range of diseases."

      Covered on